GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocular Therapeutix Inc (FRA:0OT) » Definitions » Median PS Value

Ocular Therapeutix (FRA:0OT) Median PS Value : €45.10 (As of May. 24, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Ocular Therapeutix Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Ocular Therapeutix's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.599. Ocular Therapeutix's 10-Year median PS Ratio is 75.2922. Therefore, the Median PS Value for today is €45.10.

As of today (2024-05-24), Ocular Therapeutix's share price is €5.368. Ocular Therapeutix's Median PS Value is €45.10. Therefore, Ocular Therapeutix's Price to Median PS Value for today is 0.12.

The historical rank and industry rank for Ocular Therapeutix's Median PS Value or its related term are showing as below:

FRA:0OT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12   Med: 0.19   Max: 0.19
Current: 0.12

During the past 12 years, the highest Price to Median PS Value of Ocular Therapeutix was 0.19. The lowest was 0.12. And the median was 0.19.

FRA:0OT's Price-to-Median-PS-Value is ranked better than
93.1% of 261 companies
in the Biotechnology industry
Industry Median: 0.68 vs FRA:0OT: 0.12

Ocular Therapeutix Median PS Value Historical Data

The historical data trend for Ocular Therapeutix's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocular Therapeutix Median PS Value Chart

Ocular Therapeutix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ocular Therapeutix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 44.98

Competitive Comparison of Ocular Therapeutix's Median PS Value

For the Biotechnology subindustry, Ocular Therapeutix's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Price-to-Median-PS-Value falls into.



Ocular Therapeutix Median PS Value Calculation

Ocular Therapeutix's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.599*75.2922
=45.10

10-Year Median PS Ratio is 75.2922.
Ocular Therapeutix's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.599.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocular Therapeutix  (FRA:0OT) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Ocular Therapeutix's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=5.368/45.10
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ocular Therapeutix Median PS Value Related Terms

Thank you for viewing the detailed overview of Ocular Therapeutix's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Ocular Therapeutix (FRA:0OT) Business Description

Traded in Other Exchanges
Address
24 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Ocular Therapeutix (FRA:0OT) Headlines

No Headlines